Drug intelligence / Profile preview

EDIT-202

Development stage: Discontinued
Lead developer: Shoreline Biosciences
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous, Intraperitoneal

Overview

**EDIT-202** is an investigational allogeneic induced pluripotent stem cell (iPSC)-derived natural killer (iNK) cell therapy engineered using multiplexed CRISPR-Cas12a gene editing for the treatment of solid tumors. Developed by Editas Medicine in collaboration with BlueRock Therapeutics, it enhances NK cell persistence, cytotoxicity, and resistance to tumor immunosuppression to address unmet needs in solid tumor immunotherapy. The program was discontinued by Editas in early 2023 and licensed to Shoreline Biosciences.[1][3][5][7][11][13][14]

Other names: iNK cell medicinesengineered iPSC-derived NK cell therapyiPSC-derived natural killer cell therapyinduced pluripotent stem cell-derived natural killer cell therapy

Targets

FCGR3B (Fc gamma receptor III)TGFBR2 (TGF-β receptor type 2)CISH (Cytokine-inducible SH2-containing protein)

Beyond the preview

Go deeper on EDIT-202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EDIT-202.

Explore the full profile